April 2009
Volume 50, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2009
Ocular Pharmacokinetics and Bioavailability of Topically Applied Voriconazole Solution Containing Hydroxypropyl Beta-Cyclodextrin to Rabbits
Author Affiliations & Notes
  • J. Zhang
    Henan Eye Institute, Zhengzhou, China
  • L. Wang
    Henan Eye Institute, Zhengzhou, China
  • X. Li
    Henan Eye Institute, Zhengzhou, China
  • T. Zhou
    Henan Eye Institute, Zhengzhou, China
  • H. Xia
    Henan Eye Institute, Zhengzhou, China
  • Footnotes
    Commercial Relationships  J. Zhang, None; L. Wang, None; X. Li, None; T. Zhou, None; H. Xia, None.
  • Footnotes
    Support  HNKJGrant044113061
Investigative Ophthalmology & Visual Science April 2009, Vol.50, 5959. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      J. Zhang, L. Wang, X. Li, T. Zhou, H. Xia; Ocular Pharmacokinetics and Bioavailability of Topically Applied Voriconazole Solution Containing Hydroxypropyl Beta-Cyclodextrin to Rabbits. Invest. Ophthalmol. Vis. Sci. 2009;50(13):5959.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To investigate an aqueous voriconazole (VOR) eye drop in order to increase the corneal permeability and improve ocular bioavailability following topical application.

Methods: : Hydroxypropyl beta-cyclodextrin (HP-β-CD) was used to formulate an aqueous eye drop to improve aqueous solubility of VOR. A single dose of either VOR suspension (0.5%) (VOR-SP) or VOR (0.5%)/HP-β-CD solution VOR-CD) was applied to rabbits. The aqueous humor and cornea were collected after 5,10,20,30,45,60,90 and 120min. VOR concentrations in aqueous humor and corneas were determined by HPLC after extraction.

Results: : After topically applying VOR-CD, the VOR concentrations in aqueous humor were 10.83±2.99, 11.37±3.52, 6.22±0.75, 2.89±0.71, 2.07±0.53, 0.86±0.22, 0.30±0.11 and 0.18±0.09µg/ml at 5~120min, significantly higher compared with those of VOR-SP at the corresponding time points (p < 0.05). The half-lives (t1/2) of VOR in aqueous humor for VOR-CD and VOR-SP were 37 and 20 min, respectively. The VOR-CD produced an over 1.7-fold bioavailability (AUC0-120, area under the concentration-time curve between 0 and 120 min) increase in aqueous humor over the VOR-SP. Peak VOR concentration in cornea (43.09±11.83 µg/g) was achieved within 5 min after instillation of VOR-CD, the VOR concentrations in cornea were 43.09±11.83, 41.90±7.86, 36.08±23.38, 14.02±11.29, 25.63±15.92, 29.64±11.96, 26.22±8.11 and 17.13±8.48µg/g at 5~120min, respectively, and were 2.2, 2.6, 4.9, 4.7, 1.7, 3.9, 6.0 and 4.0 times higher than those of VOR-SP at the corresponding time points, respectively. The half-lives (t1/2) of VOR in cornea for VOR-CD and VOR-SP were 241 and 298 min, respectively. The VOR-CD produced an 3.5-fold bioavailability (AUC0-120) increase in corneas over the VOR-SP.

Conclusions: : VOR-CD is superior to VOR-SP by increasing corneal peneteration and ocular bioavailability.

Keywords: cornea: basic science • antibiotics/antifungals/antiparasitics • keratitis 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×